Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Roderic O'Keeffe"'
Publikováno v:
Toxicon. 52:455-464
To ensure safety and predictable clinical efficacy, the biological activity of type A botulinum toxin (BoNT-A) preparations must remain consistent. Several methods have been employed to assess consistency but lack clinical applicability and/or are as
Autor:
Roderic O'Keeffe, Fraser E. Houston, Kati L. Houston, Stephen L. Dodd, Thomas Adams, Brian A. Hain
Publikováno v:
Journal of applied physiology (Bethesda, Md. : 1985). 119(1)
Botulinum neurotoxin type A (BoNT/A) is used clinically to induce therapeutic chemical denervation of spastically contracted skeletal muscles. However, BoNT/A administration can also cause atrophy. We sought to determine whether a major proteolytic p
Publikováno v:
European journal of neurology. 14(4)
Publikováno v:
The Botulinum J.. 1:153
Dysport? (botulinum type A toxin; BoNT-A) 500 LD50 unit vial was first licensed for clinical use in 1990. Inter-batch reproducibility and comparability of the Dysport toxin?haemagglutinin complex must ensure the consistency of clinical material. The
Autor:
M. C. Blome, B. C. Yowler, Naveed Panjwani, Andy Pickett, Cara Lynne Schengrund, Roderic O'Keeffe
Publikováno v:
The Botulinum J.. 1:88
Botulinum Type A toxin (BoNT/A)-haemagglutinin complex, marketed as Dysport?, is licensed for several clinical applications. Currently, potency is measured using the mouse lethality assay. To identify why preparations may differ, both endoprotease ac
Autor:
Andy, Pickett1, Carles, Morte2, Francesc, Pla2, Mar, Cedo2, Maribel, Mirabet2, Concepcion, Peraire2, Rosendo, Obach2, Roderic, O’Keeffe1
Publikováno v:
Toxicon. Jun2008 Supplement, Vol. 51, p18-18. 1p.